AMAG tops its year-long, activist driven transformation with a $647M selloff to private equity
AMAG Pharmaceuticals, beset by falling revenue and the threat of the FDA pulling a longtime drug, has spent the last year trying to streamline, cutting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
